Barry Ticho Sells 3,884 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Barry Ticho sold 3,884 shares of the firm’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $33,674.28. Following the transaction, the insider now directly owns 63,962 shares of the company’s stock, valued at $554,550.54. This represents a 5.72 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Stoke Therapeutics Stock Up 0.8 %

Shares of NASDAQ STOK traded up $0.07 during mid-day trading on Thursday, hitting $8.33. 1,070,583 shares of the company traded hands, compared to its average volume of 833,189. The business has a 50 day moving average of $9.50 and a two-hundred day moving average of $11.51. The stock has a market capitalization of $441.22 million, a price-to-earnings ratio of -3.97 and a beta of 0.99. Stoke Therapeutics, Inc. has a 1 year low of $5.60 and a 1 year high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.38. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The firm had revenue of $22.61 million during the quarter, compared to the consensus estimate of $4.20 million. As a group, research analysts anticipate that Stoke Therapeutics, Inc. will post -2.01 EPS for the current year.

Institutional Investors Weigh In On Stoke Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in STOK. KLP Kapitalforvaltning AS purchased a new stake in shares of Stoke Therapeutics during the 4th quarter worth about $63,000. Teacher Retirement System of Texas purchased a new stake in shares of Stoke Therapeutics during the 4th quarter worth about $113,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Stoke Therapeutics during the 4th quarter worth about $124,000. Tower Research Capital LLC TRC raised its stake in shares of Stoke Therapeutics by 70.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company’s stock worth $132,000 after purchasing an additional 4,918 shares in the last quarter. Finally, Invesco Ltd. purchased a new stake in shares of Stoke Therapeutics during the 4th quarter worth about $133,000.

Wall Street Analysts Forecast Growth

STOK has been the subject of several research reports. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 target price on shares of Stoke Therapeutics in a research note on Tuesday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. HC Wainwright reaffirmed a “buy” rating and set a $47.00 target price on shares of Stoke Therapeutics in a report on Wednesday. Finally, Chardan Capital reaffirmed a “buy” rating and set a $24.00 target price on shares of Stoke Therapeutics in a report on Wednesday. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Stoke Therapeutics currently has a consensus rating of “Buy” and an average price target of $23.00.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.